Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

266.10CHF
4:12am EDT
Change (% chg)

CHF1.60 (+0.60%)
Prev Close
CHF264.50
Open
CHF264.75
Day's High
CHF266.75
Day's Low
CHF264.60
Volume
178,648
Avg. Vol
1,865,158
52-wk High
CHF280.55
52-wk Low
CHF206.35

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 0.97
Market Cap(Mil.): CHF214,033.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.20
Yield (%): 3.31

Financials

  ROG.S Industry Sector
P/E (TTM): 22.03 29.30 32.55
EPS (TTM): 11.25 -- --
ROI: 20.46 14.23 13.83
ROE: 46.88 15.46 15.25

BRIEF-Roche Launches New Diagnostic Test For Breast And Gastric Cancer Patients

* ROCHE LAUNCHES NEW VENTANA HER2 DUAL ISH COMPANION DIAGNOSTIC TEST FOR BREAST AND GASTRIC CANCER PATIENTS ELIGIBLE FOR TARGETED THERAPY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

Apr 23 2019

BRIEF-Roche Holding AG Drugs Chief Says Hemlibra Approaching 10 Percent Market Share In Non-Inhibitor Hemophilia A Patients

* DRUGS CHIEF SAYS HEMLIBRA APPROACHING 10 PERCENT MARKET SHARE IN NON-INHIBITOR HEMOPHILIA A PATIENTS Source text for Eikon: Further company coverage:

Apr 17 2019

Roche sees no Brexit interruption for patients

ZURICH, April 17 Roche holding ag ceo says sales growth for hemlibra primarily driven by non-inhibitors patients Roche holding ag ceo says spark therapeutics acquisition planned to be completed in first half Roche holding ag ceo says still believes biosimilars will enter market in u.s. In second half Roche holding ag says sees continued "very strong" growth for ocrevus after entry of novartis's mayzent Roche holding ag drugs chief says gantenerumab for alzheimers remains a high risk

Apr 17 2019

Roche says $4.3 billion Spark offer still on track for June completion

ZURICH Roche Holding said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators continued scrutinizing it.

Apr 03 2019

UPDATE 2-Roche says $4.3 bln Spark offer still on track for June completion

* Roche says confident deal will still go through in H1 (Rewrites, adds company comment, shares, background)

Apr 03 2019

BRIEF-Roche Does Not Believe Spark Takeover Deal In Doubt

* ROCHE SAYS DOES NOT BELIEVE SPARK TAKEOVER DEAL IN DOUBT, STILL EXPECTS H1 2019 COMPLETION Source text for Eikon: Further company coverage: (Reporting by John Revill)

Apr 03 2019

Roche extends Spark offer after getting 29 pct in tender

ZURICH, April 3 Roche Holding has extended until May 2 its $4.3 billion offer for U.S. gene therapy specialist Spark Therapeutics, the Swiss drugmaker said after getting 29.4 percent of Spark's shares in a tender originally due to end on Wednesday.

Apr 03 2019

BRIEF-Roche: Ipatasertib, Tecentriq Show Promising Results in Early Phase Trial

* ROCHE'S IPATASERTIB IN COMBINATION WITH TECENTRIQ AND CHEMOTHERAPY SHOWS PROMISING ANTI-TUMOUR ACTIVITY IN TRIPLE-NEGATIVE BREAST CANCER IN EARLY PHASE TRIAL Source text: [https://bit.ly/2uBNHQb] Further company coverage: (Berlin Speed Desk)

Apr 01 2019

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

Mar 18 2019

BRIEF-Roche Presents Results Of Tecentriq Study

* ROCHE TO PRESENT RESULTS OF THE LARGEST SAFETY STUDY OF ITS KIND WITH TECENTRIQ (ATEZOLIZUMAB) IN PATIENTS WITH METASTATIC BLADDER CANCER

Mar 18 2019

Earnings vs. Estimates